

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

GLAXOSMITHKLINE PLC  
Form 6-K  
May 06, 2008

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending May 06, 2008

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F  
or Form 40-F

Form 20-F  Form 40-F  
--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No   
--

Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibility or Connected Persons

Following a re-valuation of the cash element of the notional investment held  
within the US Retirement Savings Plan ("The Plan"), which is notionally held in  
GSK Ordinary Share ADRs, the Administrators of the Plan notified GlaxoSmithKline  
plc and the under-mentioned persons on 6 May 2008 of an increase in the notional  
allocation of Ordinary Share ADRs on 1 May 2008 at a price of \$44.92 per ADR:-

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Dr J P Garnier	87
Dr M M Slaoui	3
Mrs C Bruck Slaoui	1
Mr C Viehbacher	7
Mr E J Gray	17
Dr R G Greig	142
Mr W C Louv	8
Dr D Pulman	18
Mr S M Werner	9

This notification relates to a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1) (a).

S M Bicknell  
Company Secretary

6 May 2008

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: May 06, 2008

By: VICTORIA WHYTE  
-----  
Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc